<DOC>
	<DOCNO>NCT01297166</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect LEO 27989 ointment calcipotriol plus LEO 27989 ointment , use psoriasis plaque test modify method develop KJ Dumas JR Scholtz .</brief_summary>
	<brief_title>A Psoriasis Plaque Test LEO 27989 Ointment Calcipotriol Plus LEO 27989 Ointment Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subjects understand sign informed consent form Age 18 year Males , females nonchild bear potential All skin type Subjects diagnosis psoriasis vulgaris lesion locate arm and/or legs and/or trunk . Exclusion criterion : Male willing use local contraception ( condom ) entire duration study , refrain father child within 3 month follow last study drug application Females pregnant , childbearing potential wish become pregnant study , breast feeding Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 week /5 halflives ( whichever longer ) experimental biological product prior randomisation study Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4week period prior randomisation study Subjects use one follow topical drug treatment psoriasis within 4 week period prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroid PUVA Grenz ray therapy Subjects use one follow topical drug treatment psoriasis within two week prior randomisation study : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) Topical retinoids Vitamin D analogues Topical immunomodulators ( e.g . macrolides ) Anthracen derivative Tar Salicylic acid UVB therapy Subjects use emollient target plaque within one week randomisation study Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalaria drug , lithium ACE inhibitor ) within 2 week prior randomisation study Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis Subjects known/suspected disorder calcium metabolism associate hypercalcaemia base medical history Subjects positive Hepatitis B , Hepatitis C HIV test Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week period prior randomisation longer , class substance require long washout define ( e.g. , biological treatment ) Subjects current participation interventional clinical , base interview subject Subjects know suspected hypersensitivity component ( ) investigational product History severe disease serious current condition ( base subject interview and/or result screen physical examination ) , opinion Investigator , would put subject risk participating study would interfere significantly evaluation study result study course ( e.g . cancer , severe cardiopathy , severe renal insufficiency , severe hepatic insufficiency ) . Subjects positive Hepatitis B , Hepatitis C HIV test Subjects concomitant medical dermatological disorder ( ) might preclude accurate evaluation psoriasis test area Subjects foresee intensive solar exposure study ( UV radiation , etc . ) expose within two week precede screen visit Subjects contraindication skin biopsy procedure : e.g. , allergy local anaesthetic , topical antiseptic ( chlorhexidine ) , bleed tendency , treatment anticoagulant drug , history poor wound healing , history vasovagal hypotension syncope .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>